Du benytter en nettleser vi ikke støtter. Se informasjon om nettlesere

. Referanser

  1. Louis DN, Ohgaki H, Wiestler OW, Cavenee WK, red. WHO classification of tumours of the central nervous system. 4. rev. utg. Lyon: IARC Press; 2016. Tumours of the Central nervous system
  2. Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J Neurooncol 2010;99(3):307-14.
  3. Larsen IK, red. Cancer in Norway 2015 - cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2016. Tilgjengelig fra: https://www.kreftregisteret.no/globalassets/cancer-in-norway/2015/cin2015-special_issue-web.pdf 
  4. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro Oncol 2015;17 Suppl 4:iv1-iv62.
  5. Liu Y, Li F, Zhu S, Liu M, Wu C. Clinical features and treatment of meningiomas in children: report of 12 cases and literature review. Pediatr Neurosurg 2008;44(2):112-7.
  6. Banerjee J, Paakko E, Harila M, Herva R, Tuominen J, Koivula A, et al. Radiation-induced meningiomas: a shadow in the success story of childhood leukemia. Neuro Oncol 2009;11(5):543-9.
  7. Yamanaka R, Hayano A, Kanayama T. Radiation-Induced Meningiomas: An Exhaustive Review of the Literature. World Neurosurg 2017;97:635-44.e8.
  8. Marosi C, Hassler M, Roessler K, Reni M, Sant M, Mazza E, et al. Meningioma. Crit Rev Oncol Hematol 2008;67(2):153-71.
  9. Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M, Black PM. Epidemiology of intracranial meningioma. Neurosurgery 2005;57(6):1088-95; discussion -95.
  10. Choy W, Kim W, Nagasawa D, Stramotas S, Yew A, Gopen Q, et al. The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. Neurosurg Focus 2011;30(5):E6.
  11. Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 2013;339(6123):1077-80.
  12. Abedalthagafi M, Bi WL, Aizer AA, Merrill PH, Brewster R, Agarwalla PK, et al. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol 2016;18(5):649-55.
  13. Pachow D, Andrae N, Kliese N, Angenstein F, Stork O, Wilisch-Neumann A, et al. mTORC1 inhibitors suppress meningioma growth in mouse models. Clin Cancer Res 2013;19(5):1180-9.
  14. Braganza MZ, Kitahara CM, Berrington de Gonzalez A, Inskip PD, Johnson KJ, Rajaraman P. Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review. Neuro Oncol 2012;14(11):1316-24.
  15. Friedman DL, Whitton J, Leisenring W, Mertens AC, Hammond S, Stovall M, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2010;102(14):1083-95.
  16. Taylor AJ, Little MP, Winter DL, Sugden E, Ellison DW, Stiller CA, et al. Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study. J Clin Oncol 2010;28(36):5287-93.
  17. Ron E, Modan B, Boice JD, Jr., Alfandary E, Stovall M, Chetrit A, et al. Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med 1988;319(16):1033-9.
  18. Longstreth WT, Jr., Phillips LE, Drangsholt M, Koepsell TD, Custer BS, Gehrels JA, et al. Dental X-rays and the risk of intracranial meningioma: a population-based case-control study. Cancer 2004;100(5):1026-34.
  19. Claus EB, Calvocoressi L, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M. Dental x-rays and risk of meningioma. Cancer 2012;118(18):4530-7.
  20. Lin MC, Lee CF, Lin CL, Wu YC, Wang HE, Chen CL, et al. Dental diagnostic X-ray exposure and risk of benign and malignant brain tumors. Ann Oncol 2013;24(6):1675-9.
  21. Pearce MS, Salotti JA, Little MP, McHugh K, Lee C, Kim KP, et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet 2012;380(9840):499-505.
  22. Sadetzki S, Chetrit A, Turner MC, van Tongeren M, Benke G, Figuerola J, et al. Occupational exposure to metals and risk of meningioma: a multinational case-control study. J Neurooncol 2016.
  23. Carroll RS, Zhang J, Dashner K, Sar M, Wilson EM, Black PM. Androgen receptor expression in meningiomas. J Neurosurg 1995;82(3):453-60.
  24. Blankenstein MA, Verheijen FM, Jacobs JM, Donker TH, van Duijnhoven MW, Thijssen JH. Occurrence, regulation, and significance of progesterone receptors in human meningioma. Steroids 2000;65(10-11):795-800.
  25. Carroll RS, Zhang J, Black PM. Expression of estrogen receptors alpha and beta in human meningiomas. J Neurooncol 1999;42(2):109-16.
  26. Jhawar BS, Fuchs CS, Colditz GA, Stampfer MJ. Sex steroid hormone exposures and risk for meningioma. J Neurosurg 2003;99(5):848-53.
  27. Wigertz A, Lonn S, Mathiesen T, Ahlbom A, Hall P, Feychting M, et al. Risk of brain tumors associated with exposure to exogenous female sex hormones. Am J Epidemiol 2006;164(7):629-36.
  28. Blitshteyn S, Crook JE, Jaeckle KA. Is there an association between meningioma and hormone replacement therapy? J Clin Oncol 2008;26(2):279-82.
  29. Benson VS, Pirie K, Green J, Casabonne D, Beral V, Million Women Study C. Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort. Br J Cancer 2008;99(1):185-90.
  30. Lee E, Grutsch J, Persky V, Glick R, Mendes J, Davis F. Association of meningioma with reproductive factors. Int J Cancer 2006;119(5):1152-7.
  31. Claus EB, Calvocoressi L, Bondy ML, Wrensch M, Wiemels JL, Schildkraut JM. Exogenous hormone use, reproductive factors, and risk of intracranial meningioma in females. J Neurosurg 2013;118(3):649-56.
  32. Benson VS, Kirichek O, Beral V, Green J. Menopausal hormone therapy and central nervous system tumor risk: large UK prospective study and meta-analysis. Int J Cancer 2015;136(10):2369-77.
  33. Custer BS, Koepsell TD, Mueller BA. The association between breast carcinoma and meningioma in women. Cancer 2002;94(6):1626-35.
  34. Johnson DR, Olson JE, Vierkant RA, Hammack JE, Wang AH, Folsom AR, et al. Risk factors for meningioma in postmenopausal women: results from the Iowa Women's Health Study. Neuro Oncol 2011;13(9):1011-9.
  35. Michaud DS, Bove G, Gallo V, Schlehofer B, Tjonneland A, Olsen A, et al. Anthropometric measures, physical activity, and risk of glioma and meningioma in a large prospective cohort study. Cancer Prev Res (Phila) 2011;4(9):1385-92.
  36. Wiedmann M, Brunborg C, Lindemann K, Johannesen TB, Vatten L, Helseth E, et al. Body mass index and the risk of meningioma, glioma and schwannoma in a large prospective cohort study (The HUNT Study). Br J Cancer 2013;109(1):289-94.
  37. Schildkraut JM, Calvocoressi L, Wang F, Wrensch M, Bondy ML, Wiemels JL, et al. Endogenous and exogenous hormone exposure and the risk of meningioma in men. J Neurosurg 2014;120(4):820-6.
  38. Niedermaier T, Behrens G, Schmid D, Schlecht I, Fischer B, Leitzmann MF. Body mass index, physical activity, and risk of adult meningioma and glioma: A meta-analysis. Neurology 2015;85(15):1342-50.
  39. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K, et al. Body Fatness and Cancer--Viewpoint of the IARC Working Group. N Engl J Med 2016;375(8):794-8.
  40. Preston-Martin S, Pogoda JM, Schlehofer B, Blettner M, Howe GR, Ryan P, et al. An international case-control study of adult glioma and meningioma: the role of head trauma. Int J Epidemiol 1998;27(4):579-86.
  41. Inskip PD, Mellemkjaer L, Gridley G, Olsen JH. Incidence of intracranial tumors following hospitalization for head injuries (Denmark). Cancer Causes Control 1998;9(1):109-16.
  42. Vernooij MW, Ikram MA, Tanghe HL, Vincent AJ, Hofman A, Krestin GP, et al. Incidental findings on brain MRI in the general population. N Engl J Med 2007;357(18):1821-8.
  43. Solheim O, Torsteinsen M, Johannesen TB, Jakola AS. Effects of cerebral magnetic resonance imaging in outpatients on observed incidence of intracranial tumors and patient survival: a national observational study. J Neurosurg 2014;120(4):827-32.
  44. Englot DJ, Magill ST, Han SJ, Chang EF, Berger MS, McDermott MW. Seizures in supratentorial meningioma: a systematic review and meta-analysis. J Neurosurg 2016;124(6):1552-61.
  45. Pieper DR, Al-Mefty O, Hanada Y, Buechner D. Hyperostosis associated with meningioma of the cranial base: secondary changes or tumor invasion. Neurosurgery 1999;44(4):742-6; discussion 6-7.
  46. Hanft S, Canoll P, Bruce JN. A review of malignant meningiomas: diagnosis, characteristics, and treatment. J Neurooncol 2010;99(3):433-43.  
  47. Hsu CC, Pai CY, Kao HW, Hsueh CJ, Hsu WL, Lo CP. Do aggressive imaging features correlate with advanced histopathological grade in meningiomas? J Clin Neurosci 2010;17(5):584-7.
  48. Zhang H, Rodiger LA, Shen T, Miao J, Oudkerk M. Perfusion MR imaging for differentiation of benign and malignant meningiomas. Neuroradiology 2008;50(6):525-30.
  49. Nagar VA, Ye JR, Ng WH, Chan YH, Hui F, Lee CK, et al. Diffusion-weighted MR imaging: diagnosing atypical or malignant meningiomas and detecting tumor dedifferentiation. AJNR Am J Neuroradiol 2008;29(6):1147-52.
  50. Rogers L, Gilbert M, Vogelbaum MA. Intracranial meningiomas of atypical (WHO grade II) histology. J Neurooncol 2010;99(3):393-405.
  51. Johnson MD, Powell SZ, Boyer PJ, Weil RJ, Moots PL. Dural lesions mimicking meningiomas. Hum Pathol 2002;33(12):1211-26.
  52. Tu PH, Giannini C, Judkins AR, Schwalb JM, Burack R, O'Neill BP, et al. Clinicopathologic and genetic profile of intracranial marginal zone lymphoma: a primary low-grade CNS lymphoma that mimics meningioma. J Clin Oncol 2005;23(24):5718-27.
  53. Tan LA, Kasliwal MK, Wewel J, Harbhajanka A, Arvanitis L, Moftakhar R. Neurosarcoidosis mimicking bilateral posterior fossa tentorial meningiomas. J Neurooncol 2015;125(2):435-6.
  54. Asgharian B, Chen YJ, Patronas NJ, Peghini PL, Reynolds JC, Vortmeyer A, et al. Meningiomas may be a component tumor of multiple endocrine neoplasia type 1. Clin Cancer Res 2004;10(3):869-80.
  55. Goutagny S, Kalamarides M. Meningiomas and neurofibromatosis. J Neurooncol 2010;99(3):341-7.
  56. McGaughran JM, Harris DI, Donnai D, Teare D, MacLeod R, Westerbeek R, et al. A clinical study of type 1 neurofibromatosis in north west England. J Med Genet 1999;36(3):197-203.
  57. Perry A, Giannini C, Raghavan R, Scheithauer BW, Banerjee R, Margraf L, et al. Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases. J Neuropathol Exp Neurol 2001;60(10):994-1003.
  58. Larson JJ, van Loveren HR, Balko MG, Tew JM, Jr. Evidence of meningioma infiltration into cranial nerves: clinical implications for cavernous sinus meningiomas. J Neurosurg 1995;83(4):596-9.
  59. Torres-Martin M, Kusak ME, Isla A, Burbano RR, Pinto GR, Melendez B, et al. Whole exome sequencing in a case of sporadic multiple meningioma reveals shared NF2, FAM109B, and TPRXL mutations, together with unique SMARCB1 alterations in a subset of tumor nodules. Cancer Genet 2015;208(6):327-32.
  60. Go RS, Taylor BV, Kimmel DW. The natural history of asymptomatic meningiomas in Olmsted County, Minnesota. Neurology 1998;51(6):1718-20.
  61. Nakamura M, Roser F, Michel J, Jacobs C, Samii M. The natural history of incidental meningiomas. Neurosurgery 2003;53(1):62-70; discussion -1.
  62. Yano S, Kuratsu J, Kumamoto Brain Tumor Research G. Indications for surgery in patients with asymptomatic meningiomas based on an extensive experience. J Neurosurg 2006;105(4):538-43.
  63. Herscovici Z, Rappaport Z, Sulkes J, Danaila L, Rubin G. Natural history of conservatively treated meningiomas. Neurology 2004;63(6):1133-4.
  64. Meling TR, Da Broi M, Scheie D, Helseth E, Smoll NR. Meningioma Surgery-Are We Making Progress? World Neurosurg 2019;125:e205-e13.
  65. Aizer AA, Bi WL, Kandola MS, Lee EQ, Nayak L, Rinne ML, et al. Extent of resection and overall survival for patients with atypical and malignant meningioma. Cancer 2015;121(24):4376-81.
  66. Meling TR, Da Broi M, Scheie D, Helseth E. Meningiomas: skull base versus non-skull base. Neurosurg Rev 2019;42(1):163-73.
  67. Lemée JM, Corniola MV, Da Broi M, Joswig H, Scheie D, Schaller K, et al. Extent of Resection in Meningioma: Predictive Factors and Clinical Implications. Sci Rep 2019;9(1):5944.
  68. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 1957;20(1):22-39.
  69. Stafford SL, Perry A, Suman VJ, Meyer FB, Scheithauer BW, Lohse CM, et al. Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clin Proc 1998;73(10):936-42.
  70. Kallio M, Sankila R, Hakulinen T, Jaaskelainen J. Factors affecting operative and excess long-term mortality in 935 patients with intracranial meningioma. Neurosurgery 1992;31(1):2-12.
  71. Hasseleid BF, Meling TR, Ronning P, Scheie D, Helseth E. Surgery for convexity meningioma: Simpson Grade I resection as the goal: clinical article. J Neurosurg 2012;117(6):999-1006.
  72. Meling TR, Da Broi M, Scheie D, Helseth E. Skull base versus non-skull base meningioma surgery in the elderly. Neurosurg Rev 2019;42(4):961-72.
  73. Lemée JM, Corniola MV, Da Broi M, Schaller K, Meling TR. Early Postoperative Complications in Meningioma: Predictive Factors and Impact on Outcome. World Neurosurg 2019;128:e851-e8.
  74. Corniola MV, Lemée JM, Schaller K, Meling TR. Lateral sphenoid wing meningiomas without bone invasion-still skull base surgery? Neurosurg Rev 2019;Oct 29 [Epub ahead of print].
  75. Corniola MV, Lemée JM, Da Broi M, Joswig H, Schaller K, Helseth E, et al. Posterior fossa meningiomas: perioperative predictors of extent of resection, overall survival and progression-free survival. Acta Neurochir (Wien) 2019;161(5):1003-11.
  76. Giammattei L, Starnoni D, Cossu G, Bruneau M, Cavallo LM, Cappabianca P, et al. Surgical management of Tuberculum sellae Meningiomas: Myths, facts, and controversies. Acta Neurochir (Wien) 2020;162(3):631-40.
  77. Korah MP, Nowlan AW, Johnstone PA, Crocker IR. Radiation therapy alone for imaging-defined meningiomas. Int J Radiat Oncol Biol Phys 2010;76(1):181-6.
  78. Soyuer S, Chang EL, Selek U, Shi W, Maor MH, DeMonte F. Radiotherapy after surgery for benign cerebral meningioma. Radiother Oncol 2004;71(1):85-90.
  79. Rogers L, Mehta M. Role of radiation therapy in treating intracranial meningiomas. Neurosurg Focus 2007;23(4):E4.
  80. Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raizer J, et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg 2015;122(1):4-23.
  81. Glaholm J, Bloom HJ, Crow JH. The role of radiotherapy in the management of intracranial meningiomas: the Royal Marsden Hospital experience with 186 patients. Int J Radiat Oncol Biol Phys 1990;18(4):755-61.
  82. Forbes AR, Goldberg ID. Radiation therapy in the treatment of meningioma: the Joint Center for Radiation Therapy experience 1970 to 1982. J Clin Oncol 1984;2(10):1139-43.
  83. Taylor BW, Jr., Marcus RB, Jr., Friedman WA, Ballinger WE, Jr., Million RR. The meningioma controversy: postoperative radiation therapy. Int J Radiat Oncol Biol Phys 1988;15(2):299-304.
  84. Aghi MK, Carter BS, Cosgrove GR, Ojemann RG, Amin-Hanjani S, Martuza RL, et al. Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery 2009;64(1):56-60; discussion
  85. Park HJ, Kang HC, Kim IH, Park SH, Kim DG, Park CK, et al. The role of adjuvant radiotherapy in atypical meningioma. J Neurooncol 2013;115(2):241-7.
  86. Sughrue ME, Sanai N, Shangari G, Parsa AT, Berger MS, McDermott MW. Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas. J Neurosurg 2010;113(2):202-9.
  87. Yang SY, Park CK, Park SH, Kim DG, Chung YS, Jung HW. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatry 2008;79(5):574-80.
  88. Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC. "Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer 1999;85(9):2046-56.
  89. Aizer AA, Arvold ND, Catalano P, Claus EB, Golby AJ, Johnson MD, et al. Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. Neuro Oncol 2014;16(11):1547-53.
  90. Kaur G, Sayegh ET, Larson A, Bloch O, Madden M, Sun MZ, et al. Adjuvant radiotherapy for atypical and malignant meningiomas: a systematic review. Neuro Oncol 2014;16(5):628-36.
  91. Rogers L, Zhang P, Vogelbaum MA, Perry A, Ashby LS, Modi JM, et al. Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg 2018;129(1):35-47.
  92. Jenkinson MD, Javadpour M, Haylock BJ, Young B, Gillard H, Vinten J, et al. The ROAM/EORTC-1308 trial: Radiation versus Observation following surgical resection of Atypical Meningioma: study protocol for a randomised controlled trial. Trials 2015;16:519.
  93. Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery [pågående studie]. 2017-2027. NCT03180268. Tilgjengelig fra: https://clinicaltrials.gov/ct2/show/study/NCT03180268 
  94. Weber DC, Ares C, Villa S, Peerdeman SM, Renard L, Baumert BG, et al. Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: A phase-II parallel non-randomized and observation study (EORTC 22042-26042). Radiother Oncol 2018;128(2):260-5.
  95. Lee JY, Niranjan A, McInerney J, Kondziolka D, Flickinger JC, Lunsford LD. Stereotactic radiosurgery providing long-term tumor control of cavernous sinus meningiomas. J Neurosurg 2002;97(1):65-72.
  96. Hakim R, Alexander E, 3rd, Loeffler JS, Shrieve DC, Wen P, Fallon MP, et al. Results of linear accelerator-based radiosurgery for intracranial meningiomas. Neurosurgery 1998;42(3):446-53; discussion 53-4.
  97. Nicolato A, Foroni R, Alessandrini F, Bricolo A, Gerosa M. Radiosurgical treatment of cavernous sinus meningiomas: experience with 122 treated patients. Neurosurgery 2002;51(5):1153-9; discussion 9-61.
  98. Kondziolka D, Flickinger JC, Perez B. Judicious resection and/or radiosurgery for parasagittal meningiomas: outcomes from a multicenter review. Gamma Knife Meningioma Study Group. Neurosurgery 1998;43(3):405-13; discussion 13-4.
  99. Pollock BE, Stafford SL, Link MJ, Garces YI, Foote RL. Single-fraction radiosurgery for presumed intracranial meningiomas: efficacy and complications from a 22-year experience. Int J Radiat Oncol Biol Phys 2012;83(5):1414-8.
  100. Maclean J, Fersht N, Short S. Controversies in radiotherapy for meningioma. Clin Oncol (R Coll Radiol) 2014;26(1):51-64.
  101. Bloch O, Kaur G, Jian BJ, Parsa AT, Barani IJ. Stereotactic radiosurgery for benign meningiomas. J Neurooncol 2012;107(1):13-20.
  102. Skeie BS, Enger PO, Skeie GO, Thorsen F, Pedersen PH. Gamma knife surgery of meningiomas involving the cavernous sinus: long-term follow-up of 100 patients. Neurosurgery 2010;66(4):661-8; discussion 8-9.
  103. Eaton DJ, Lee J, Patel R, Millin AE, Paddick I, Walker C. Stereotactic radiosurgery for benign brain tumors: Results of multicenter benchmark planning studies. Pract Radiat Oncol 2018;8(5):e295-e304.
  104. Park KJ, Kano H, Iyer A, Liu X, Tonetti DA, Lehocky C, et al. Gamma Knife stereotactic radiosurgery for cavernous sinus meningioma: long-term follow-up in 200 patients. J Neurosurg 2018;Jul:[Epub ahead of print].
  105. Combs SE, Farzin M, Boehmer J, Oehlke O, Molls M, Debus J, et al. Clinical outcome after high-precision radiotherapy for skull base meningiomas: Pooled data from three large German centers for radiation oncology. Radiother Oncol 2018;127(2):274-9.
  106. Spiegelmann R, Cohen ZR, Nissim O, Alezra D, Pfeffer R. Cavernous sinus meningiomas: a large LINAC radiosurgery series. J Neurooncol 2010;98(2):195-202.
  107. Debus J, Wuendrich M, Pirzkall A, Hoess A, Schlegel W, Zuna I, et al. High efficacy of fractionated stereotactic radiotherapy of large base-of-skull meningiomas: long-term results. J Clin Oncol 2001;19(15):3547-53.
  108. Milker-Zabel S, Zabel A, Schulz-Ertner D, Schlegel W, Wannenmacher M, Debus J. Fractionated stereotactic radiotherapy in patients with benign or atypical intracranial meningioma: long-term experience and prognostic factors. Int J Radiat Oncol Biol Phys 2005;61(3):809-16.
  109. Arvold ND, Lessell S, Bussiere M, Beaudette K, Rizzo JF, Loeffler JS, et al. Visual outcome and tumor control after conformal radiotherapy for patients with optic nerve sheath meningioma. Int J Radiat Oncol Biol Phys 2009;75(4):1166-72.
  110. Minniti G, Amichetti M, Enrici RM. Radiotherapy and radiosurgery for benign skull base meningiomas. Radiat Oncol 2009;4:42.
  111. Coskun M, Straube W, Hurkmans CW, Melidis C, de Haan PF, Villa S, et al. Quality assurance of radiotherapy in the ongoing EORTC 22042-26042 trial for atypical and malignant meningioma: results from the dummy runs and prospective individual case Reviews. Radiat Oncol 2013;8:23.
  112. Combs SE, Adeberg S, Dittmar JO, Welzel T, Rieken S, Habermehl D, et al. Skull base meningiomas: Long-term results and patient self-reported outcome in 507 patients treated with fractionated stereotactic radiotherapy (FSRT) or intensity modulated radiotherapy (IMRT). Radiother Oncol 2013;106(2):186-91.
  113. Kessel KA, Fischer H, Oechnser M, Zimmer C, Meyer B, Combs SE. High-precision radiotherapy for meningiomas : Long-term results and patient-reported outcome (PRO). Strahlenther Onkol 2017;193(11):921-30.
  114. Adeberg S, Hartmann C, Welzel T, Rieken S, Habermehl D, von Deimling A, et al. Long-term outcome after radiotherapy in patients with atypical and malignant meningiomas--clinical results in 85 patients treated in a single institution leading to optimized guidelines for early radiation therapy. Int J Radiat Oncol Biol Phys 2012;83(3):859-64.
  115. Press RH, Prabhu RS, Appin CL, Brat DJ, Shu HK, Hadjipanayis C, et al. Outcomes and patterns of failure for grade 2 meningioma treated with reduced-margin intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 2014;88(5):1004-10.
  116. Kaul D, Budach V, Misch M, Wiener E, Exner S, Badakhshi H. Meningioma of the skull base: long-term outcome after image-guided stereotactic radiotherapy. Cancer Radiother 2014;18(8):730-5.
  117. Halasz LM, Bussiere MR, Dennis ER, Niemierko A, Chapman PH, Loeffler JS, et al. Proton stereotactic radiosurgery for the treatment of benign meningiomas. Int J Radiat Oncol Biol Phys 2011;81(5):1428-35.
  118. Combs SE, Hartmann C, Nikoghosyan A, Jakel O, Karger CP, Haberer T, et al. Carbon ion radiation therapy for high-risk meningiomas. Radiother Oncol 2010;95(1):54-9.
  119. Grunberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, Russell CA, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 1991;74(6):861-6.
  120. Ji Y, Rankin C, Grunberg S, Sherrod AE, Ahmadi J, Townsend JJ, et al. Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 2015;33(34):4093-8.
  121. Goodwin JW, Crowley J, Eyre HJ, Stafford B, Jaeckle KA, Townsend JJ. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol 1993;15(1):75-7.
  122. Wen PY, Quant E, Drappatz J, Beroukhim R, Norden AD. Medical therapies for meningiomas. J Neurooncol 2010;99(3):365-78.
  123. Chamberlain MC. Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma. J Neurooncol 2012;107(2):315-21.
  124. Chamberlain MC, Tsao-Wei DD, Groshen S. Temozolomide for treatment-resistant recurrent meningioma. Neurology 2004;62(7):1210-2.
  125. Chamberlain MC. Adjuvant combined modality therapy for malignant meningiomas. J Neurosurg 1996;84(5):733-6.
  126. Koper JW, Zwarthoff EC, Hagemeijer A, Braakman R, Avezaat CJ, Bergstrom M, et al. Inhibition of the growth of cultured human meningioma cells by recombinant interferon-alpha. Eur J Cancer 1991;27(4):416-9.
  127. Kaba SE, DeMonte F, Bruner JM, Kyritsis AP, Jaeckle KA, Levin V, et al. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery 1997;40(2):271-5.
  128. Muhr C, Gudjonsson O, Lilja A, Hartman M, Zhang ZJ, Langstrom B. Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography. Clin Cancer Res 2001;7(8):2269-76.
  129. Chamberlain MC, Glantz MJ. Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer 2008;113(8):2146-51.
  130. Runzi MW, Jaspers C, Windeck R, Benker G, Mehdorn M, Reinhardt V, et al. Treatment of meningioma with octreotide. Lancet 1989;2(8656):217-8.
  131. Simo M, Argyriou AA, Macia M, Plans G, Majos C, Vidal N, et al. Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy. Cancer Chemother Pharmacol 2014;73(5):919-23.
  132. Norden AD, Ligon KL, Hammond SN, Muzikansky A, Reardon DA, Kaley TJ, et al. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology 2015;84(3):280-6.
  133. Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol 2009;11(6):853-60.
  134. Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon JE, 2nd, Coan A, et al. Phase II study of Gleevec(R) plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol 2012;106(2):409-15.
  135. Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol 2010;96(2):211-7.
  136. Nayak L, Iwamoto FM, Rudnick JD, Norden AD, Lee EQ, Drappatz J, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol 2012;109(1):187-93.
  137. Kaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol 2015;17(1):116-21.
  138. Sawaya R, Zuccarello M, Elkalliny M, Nishiyama H. Postoperative venous thromboembolism and brain tumors: Part I. Clinical profile. J Neurooncol 1992;14(2):119-25.
  139. Kshettry VR, Ostrom QT, Kruchko C, Al-Mefty O, Barnett GH, Barnholtz-Sloan JS. Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States. Neuro Oncol 2015;17(8):1166-73.
  140. Sahm F, Schrimpf D, Stichel D, Jones DTW, Hielscher T, Schefzyk S, et al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol 2017;18(5):682-94.
  141. Nasjonal helseplan (2007–2010). Oslo: Helse- og omsorgsdepartementet; 2006. Særtrykk av St.prp. nr. 1 (2006–2007) kapittel 6. Tilgjengelig fra: https://www.regjeringen.no/globalassets/upload/hod/sykehus/nasjonal_helseplan_sartrykk.pdf 
  142. Lov om kommunale helse- og omsorgstjenester m.m. (helse- og omsorgstjenesteloven). LOV-2011-06-24-30. Sist endret i: LOV-2019-06-21-45 fra 01.01.2020. Tilgjengelig fra: https://lovdata.no/dokument/NL/lov/2011-06-24-30 
  143. Nasjonal strategi for kreftområdet 2006-2009. Oslo: Helse- og omsorgsdepartementet; 2006. Tilgjengelig fra: https://www.regjeringen.no/no/dokumenter/nasjonal-strategi-for-kreftomradet/id446845/ 
  144. Sammen - mot kreft: nasjonal kreftstrategi 2013-2017. Oslo: Helse- og omsorgsdepartementet; 2013. Tilgjengelig fra: https://www.regjeringen.no/no/dokumenter/sammen---mot-kreft/id728818/ 
  145. Leve med kreft: nasjonal kreftstrategi (2018–2022). Oslo: Helse- og omsorgsdepartementet; 2018. Tilgjengelig fra: https://www.regjeringen.no/no/dokumenter/leve-med-kreft/id2598282/ 
  146. Levernes S. Faglige anbefalinger for nomenklatur for volumer i stråleterapi. Østerås: Direktoratet for strålevern og atomsikkerhet; 2019. Teknisk dokument 14. Tilgjengelig fra: https://dsa.no/publikasjoner/_/attachment/download/9d2a42a5-241e-4299-86cf-6b02a0abf3b9:2400dff7cb71f4bff583473d690fcb79650dd59e/TekniskDokument14_rev2020.pdf 
  147. Marienhagen K, Djupvik LH, Danielsen T. Faglige anbefalinger for inntegning av risikoorganer i CNS. Østerås: Direktoratet for strålevern og atomsikkerhet; 2020. Teknisk dokument 16. Tilgjengelig fra: https://dsa.no/publikasjoner/_/attachment/download/401a60b3-b7db-4c4a-b741-da0a70c43b20:f0c3325a0ec4a43b2335cf17df266e4e7c34408c/Teknisk%20dokument16_rev.pdf 
  148. Levernes S. Volum og doser i ekstern stråleterapi: definisjoner og anbefalinger. Østerås: Statens strålevern; 2012. StrålevernRapport 2012:9. Tilgjengelig fra: https://dsa.no/medisinsk-stralebruk/kvist/_/attachment/download/bee8860b-36d1-42e7-8d64-f5ad4fcef2e8:8ebb86decddc2818ec31e4999d26cdf7aec14ac2/StralevernRapport_09-2012.pdf 
  149. Report 78: Prescribing, Recording, and Reporting Proton-Beam Therapy. Journal of the ICRU 2007;7(7).
  150. Report 83: Prescribing, Recording, and Reporting Intensity-Modulated Photon-Beam Therapy (IMRT). Journal of the ICRU 2010;10(1).
  151. Landberg T, Chavaudra J, Dobbs J, Gerard JP, Hanks G, Horiot JC, et al. Report 62: prescribing, Recording and Reporting Photon Beam Therapy (Supplement to ICRU report 50). Journal of the ICRU 1999;os32(1).
  152. Landberg T, Chavaudra J, Dobbs J, Hanks G, Johansson K-A, Möller T, et al. Report 50: Prescribing, Recording, and Reporting Photon Beam Therapy. Journal of the ICRU 1993;os26(1).

Sist faglig oppdatert: 31. desember 2020